Terms: = Breast cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 AND Treatment
652 results:
1. Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human breast cancer.
Wescott EC; Sun X; Gonzalez-Ericsson P; Hanna A; Taylor BC; Sanchez V; Bronzini J; Opalenik SR; Sanders ME; Wulfkuhle J; Gallagher RI; Gomez H; Isaacs C; Bharti V; Wilson JT; Ballinger TJ; Santa-Maria CA; Shah PD; Dees EC; Lehmann BD; Abramson VG; Hirst GL; Brown Swigart L; van ˈt Veer LJ; Esserman LJ; Petricoin EF; Pietenpol JA; Balko JM
Cancer Res Commun; 2024 Apr; 4(4):1120-1134. PubMed ID: 38687247
[TBL] [Abstract] [Full Text] [Related]
2. Crosstalk of disulfidptosis-related subtypes identifying a prognostic signature to improve prognosis and immunotherapy responses of clear cell renal cell carcinoma patients.
Ren L; Liu J; Lin Q; He T; Huang G; Wang W; Zhan X; He Y; Huang B; Mao X
BMC Genomics; 2024 Apr; 25(1):413. PubMed ID: 38671348
[TBL] [Abstract] [Full Text] [Related]
3. pd-1 inhibition with retifanlimab and/or arginase inhibition with INCB001158 in Japanese patients with solid tumors: A phase I study.
Kuboki Y; Koyama T; Matsubara N; Naito Y; Kondo S; Harano K; Yonemori K; Yoh K; Gu Y; Mita T; Chen X; Ueda E; Yamamoto N; Doi T; Shimizu T
Cancer Med; 2024 Apr; 13(8):e6980. PubMed ID: 38651187
[TBL] [Abstract] [Full Text] [Related]
4. Chitin-mediated blockade of chitinase-like proteins reduces tumor immunosuppression, inhibits lymphatic metastasis and enhances anti-pd-1 efficacy in complementary TNBC models.
Salembier R; De Haes C; Bellemans J; Demeyere K; Van Den Broeck W; Sanders NN; Van Laere S; Lyons TR; Meyer E; Steenbrugge J
Breast Cancer Res; 2024 Apr; 26(1):63. PubMed ID: 38605414
[TBL] [Abstract] [Full Text] [Related]
5. Harnessing pd-1 cell membrane-coated paclitaxel dimer nanoparticles for potentiated chemoimmunotherapy.
Hu N; Xue H; Zhang T; Fan Y; Guo F; Li Z; Huo M; Guan X; Chen G
Biomed Pharmacother; 2024 May; 174():116482. PubMed ID: 38520866
[TBL] [Abstract] [Full Text] [Related]
6. A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors.
Juric D; Barve M; Vaishampayan U; Roda D; Calvo A; Jañez NM; Trigo J; Greystoke A; Harvey RD; Olszanski AJ; Opyrchal M; Spira A; Thistlethwaite F; Jiménez B; Sappal JH; Kannan K; Riley J; Li C; Li C; Gregory RC; Miao H; Wang S
Cancer Med; 2024 Mar; 13(5):. PubMed ID: 38501219
[TBL] [Abstract] [Full Text] [Related]
7. Oncolytic vaccinia virus immunotherapy antagonizes image-guided radiotherapy in mouse mammary tumor models.
Umer BA; Noyce RS; Kieser Q; Favis NA; Shenouda MM; Rans KJ; Middleton J; Hitt MM; Evans DH
PLoS One; 2024; 19(3):e0298437. PubMed ID: 38498459
[TBL] [Abstract] [Full Text] [Related]
8. The enhanced antitumor activity of bispecific antibody targeting pd-1/PD-L1 signaling.
Li T; Niu M; Zhou J; Wu K; Yi M
Cell Commun Signal; 2024 Mar; 22(1):179. PubMed ID: 38475778
[TBL] [Abstract] [Full Text] [Related]
9. MGP
Chang K; Jiao Y; Zhang B; Hou L; He X; Wang D; Li D; Li R; Wang Z; Fan P; Zhang J
Int Immunopharmacol; 2024 Apr; 131():111818. PubMed ID: 38460300
[TBL] [Abstract] [Full Text] [Related]
10. Fucoidan enhances the anti-tumor effect of anti-pd-1 immunotherapy by regulating gut microbiota.
Li H; Dong T; Tao M; Zhao H; Lan T; Yan S; Gong X; Hou Q; Ma X; Song Y
Food Funct; 2024 Apr; 15(7):3463-3478. PubMed ID: 38456333
[TBL] [Abstract] [Full Text] [Related]
11. Combination of STAT3 inhibitor with Herceptin reduced immune checkpoints expression and provoked anti-breast cancer immunity: An in vitro study.
Jahangiri A; Ezzeddini R; Zounemat Kermani N; Bahrami F; Salek Farrokhi A
Scand J Immunol; 2023 Sep; 98(3):e13300. PubMed ID: 38441231
[TBL] [Abstract] [Full Text] [Related]
12. K48-linked deubiquitination of VGLL4 by USP15 enhances the efficacy of tumor immunotherapy in triple-negative breast cancer.
Wang X; Deng X; Hu J; Zheng W; Ye D; Zhou X; Fang L
Cancer Lett; 2024 Apr; 588():216764. PubMed ID: 38431034
[TBL] [Abstract] [Full Text] [Related]
13. Preoperative single-dose camrelizumab and/or microwave ablation in women with early-stage breast cancer: A window-of-opportunity trial.
Pan H; Yu M; Tang X; Mao X; Liu M; Zhang K; Qian C; Wang J; Xie H; Qiu W; Ding Q; Wang S; Zhou W
Med; 2024 Apr; 5(4):291-310.e5. PubMed ID: 38417440
[TBL] [Abstract] [Full Text] [Related]
14. An innovative antibody fusion protein targeting PD-L1, VEGF and TGF-β with enhanced antitumor efficacies.
Fan W; Chen Y; Zhou Z; Duan W; Yang C; Sheng S; Wang Y; Wei X; Liu Y; Huang Y
Int Immunopharmacol; 2024 Mar; 130():111698. PubMed ID: 38377856
[TBL] [Abstract] [Full Text] [Related]
15. Sintilimab with two cycles of chemotherapy for the treatment of advanced squamous non-small cell lung cancer: a phase 2 clinical trial.
Zhang M; Zhang G; Niu Y; Zhang G; Ji Y; Yan X; Zhang X; Wang Q; Jing X; Wang J; Ma Z; Wang H
Nat Commun; 2024 Feb; 15(1):1512. PubMed ID: 38374204
[TBL] [Abstract] [Full Text] [Related]
16. Progress of pd-1/PD-L1 inhibitor combination therapy in immune treatment for HER2-positive tumors.
Zhao S; Qiu Y; Yuan M; Wang Z
Eur J Clin Pharmacol; 2024 May; 80(5):625-638. PubMed ID: 38342825
[TBL] [Abstract] [Full Text] [Related]
17. Immunological characterization of a long-lasting response in a patient with metastatic triple-negative breast cancer treated with pd-1 and LAG-3 blockade.
Rivoltini L; Camisaschi C; Fucà G; Paolini B; Vergani B; Beretta V; Damian S; Duca M; Cresta S; Magni M; Leone BE; Castelli C; de Braud F; De Santis F; Di Nicola M
Sci Rep; 2024 Feb; 14(1):3379. PubMed ID: 38336861
[TBL] [Abstract] [Full Text] [Related]
18. Prognostic implication of novel immune-related signature in breast cancer.
Chen B; Wu H; Fang Y; Huang G; Guo C; Chen C; He L; Chen Z; Hou X; Li C; Wu J
Medicine (Baltimore); 2024 Feb; 103(6):e37065. PubMed ID: 38335435
[TBL] [Abstract] [Full Text] [Related]
19. Immunotherapy for non-small cell lung cancer.
Kagamu H
Respir Investig; 2024 Mar; 62(2):307-312. PubMed ID: 38310751
[TBL] [Abstract] [Full Text] [Related]
20. Relationship between immune checkpoint proteins and neoadjuvant chemotherapy response in breast cancer.
Kina Kilicaslan U; Aru B; Aydin Aksu S; Vardar Aker F; Yanikkaya Demirel G; Gurleyik MG
Surg Oncol; 2024 Feb; 52():102037. PubMed ID: 38290327
[TBL] [Abstract] [Full Text] [Related]
[Next]
